PET/CT imaging in different types of lung cancer: An overview

European Journal of Radiology

Volumn 81, Issue 5, 2012, Pages 988-1001

  Ambrosini, Valentina ^a   Nicolini, Silvia ^a   Caroli, Paola ^a   Nanni, Cristina ^a   Massaro, Arianna ^b   Marzola, Maria Cristina ^b   Rubello, Domenico ^b   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

18F DOPA; 18F FDG; 68Ga DOTA peptides; Drawbacks; Indications; Lung cancer; PET CT; Various types

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM 68; METIROSINE; TETRAXETAN;

ADRENAL METASTASIS; BONE METASTASIS; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CENTRAL NERVOUS SYSTEM METASTASIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NEUROENDOCRINE TUMOR; PLEURA EFFUSION; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY;

FEMALE; HUMANS; IMAGE ENHANCEMENT; LUNG NEOPLASMS; MALE; POSITRON-EMISSION TOMOGRAPHY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84860008181     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2011.03.020     Document Type: Review

References (180)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R, EUROCARE Working Group. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009;45:931-91.
3. Schwartz AG, Prysak GM, Bock CH, Cote ML. The molecular epidemiology of lung cancer. Carcinogenesis 2007;28:507-18. (Pubitemid 46523346)
4. Youlden DR, Cramb SM, Baade PD. The International epidemiology of lung cancer geographical distribution and secular trends. J Thorac Oncol 2008;3:819-31.
5. Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. Lancet Oncol 2010 [Epub ahead of print].
6. Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest 2007;132:185-92. (Pubitemid 47068220)
7. Subramanian J, Velcheti V, Gao F, Govindan R. Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2:827-30. (Pubitemid 47361024)
8. Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol 2007;25:472-8. (Pubitemid 350002951)
9. Samet JM, Avila-Tang E, Boffetta P, et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res 2009;15:5626-45.
10. American Cancer Society. Detailed guide: lung cancer non-small cell. What is non-small cell lung cancer? American Cancer Society; 2010.
11. Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 2010. November 15 [Epub ahead of print].
12. Devesa SS, Bray F, Vizcaino P, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005;117:294-9. (Pubitemid 41379403)
13. Boffetta P, Jayaprakash V, Yang P, et al. Tobacco smoking as a risk factor of bronchioloalveolar carcinoma of the lung: pooled analysis of seven casecontrol studies in the International Lung Cancer Consortium (ILCCO). Cancer Causes Control 2010. November 12 [Epub ahead of print].
14. Ginsberg MS, Grewal RK, Heelan RT. Lung cancer. Radiol Clin North Am 2007;45:21-43. (Pubitemid 44854042)
15. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385-96. (Pubitemid 41443406)
16. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13715 carcinoid tumors. Cancer 2003;97:934-59. (Pubitemid 36173145)
17. Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol 2008;20:1-12. (Pubitemid 350190975)
18. Saif MW, Tzannou I, Makrilia N, Syrigos K. Role and cost effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med 2010;83:53-65.
19. Jadvar H, Alavi A, Gambhir SS. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med 2009;50:1820-7.
20. Divisi D, Di Tommaso S, Di Leonardo G, Brianzoni E, De Vico A, Crisci R. 18-Fluorine fluorodeoxyglucose positron emission tomography with computerized tomography versus computerized tomography alone for the management of solitary lung nodules with diameters inferior to 1.5 cm. Thorac Cardiovasc Surg 2010;58:422-6.
21. Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CGO. Revisiting the prognostic value of preoperative 18F-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging 2010;37:691-8.
22. Pommier P, Touboul E, Chabaud S, et al. Impact of (18)F-FDG PET on treatment strategy and 3D radiotherapy planning in non-small cell lung cancer: a prospective multicenter study. AJR Am J Roentgenol 2010;195:350-5.
23. de Cabanyes Candela S, Detterbeck FC. A systematic review of restaging after induction therapy for stage IIIa lung cancer: prediction of pathologic stage. J Thorac Oncol 2010;5:389-98.
24. Fischer BM, Mortensen J, Langer SW, et al. PET/CT imaging in response evaluation of patients with small cell lung cancer. Lung Cancer 2006;54:41-9.
25. Yang W, Zhang Y, Fu Z, et al. Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2010;37:1291-9.
26. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47. (Pubitemid 34110469)
27. Pillot G, Siegel BA, Govindan R. Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review. J Thorac Oncol 2006;1:152-9. (Pubitemid 47164003)
28. de Geus-Oei LF, van der Heijden HF, Corstens FH, Oven WJ. Predictive and prognostic value of FDG-PET in nonsmall cell lung cancer: a systematic review. Cancer 2007;110:1654-64. (Pubitemid 47557290)
29. Quint LE. Saging non-small cell lung cancer. Cancer Imaging 2007 Oct 22;7:148-59.
30. Silvestri GA, Gould MK, Margolis ML, et al. Noninvasive staging of nonsmall cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). American College of Chest Physicians. Chest 2007;132(3 Suppl.):178S-201S. (Pubitemid 47502807)
31. Schreyögg J, Weller J, Stargardt T, et al. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer. J Nucl Med 2010;51:1668-75.
32. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14. (Pubitemid 47357522)
33. Goldstraw P. The 7th edition of TNM in lung cancer: what now? J Thorac Oncol 2009;4:671-3.
34. Rena O, Massera F, Robustellini M, et al. Use of the proposals of the international association for the study of lung cancer in the forthcoming edition of lung cancer staging system to predict long-term prognosis of operated patients. Cancer J 2010;16:176-81.
35. Lardinois D, Weder W, Hany TF, et al. Staging of non-small cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-7. (Pubitemid 36706537)
36. De Wever W, Ceyssens S, Mortelmans L, et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 2007;17:23-32. (Pubitemid 46063025)
37. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003;229:526-33. (Pubitemid 37310842)
38. Light RW, Erozan YS, Ball WC. Cells in pleural fluid. Their value in differential diagnosis. Arch Intern Med 1973;132:854-60.
39. Gupta NC, Rogers JS, Graeber GM, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest 2002;122:1918-24. (Pubitemid 36051125)
40. Erasmus JJ, McAdams HP, Rossi SE, Goodman PC, Coleman RE, Patz EF. FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol 2000;175:245-9. (Pubitemid 30415572)
41. Schaffler GJ, Wolf G, Schoellnast H, et al. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET. Radiology 2004;231:858-65. (Pubitemid 38668109)
42. Higashi K, Ueda Y, Yagishita M, et al. measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 2000;41:85-92. (Pubitemid 30046688)
43. Higashi K, Ito K, Hiramatsu Y, et al. 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. J Nucl Med 2005;46:267-73. (Pubitemid 43073434)
44. Nomori H, Watanabe K, Ohtsuka T, et al. Fluorine 18-tagged fluorodeoxyglucose positron emission tomographic scanning to predict lymph node metastasis, invasiveness, or both, in clinical T1 N0 M0 lung adenocarcinoma. J Thorac Cardiovasc Surg 2004;128:396-401. (Pubitemid 39194695)
45. Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging 2010;37:691-8.
46. Davies A, Tan C, Paschalides C, et al. FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer 2007;55:75-8. (Pubitemid 46038876)
47. Goodgame B, Pillot GA, Yang Z, et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol 2008;3:130-4. (Pubitemid 351323186)
48. Hanin FX, Lonneux M, Cornet J, et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg 2008;33:819-23.
49. Downey RJ, Akhurst T, Gonen M, Park B, Rusch V. Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer. J Thorac Cardiovasc Surg 2007;133:1419-27.
50. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005;130:151-9. (Pubitemid 40941684)
51. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon II JE, Patz Jr EF. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol 2008;26:1459-64.
52. Kaira K, Oriuchi N, Shimizu K, et al. Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-α-methyl tyrosine uptake in outcome of non-small cell lung cancer. Nucl Med Biol 2010;37:911-6.
53. Kaira K, Oriuchi N, Shimizu K, et al. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med 2009;50:1770-6.
54. Robinson LA, Ruckdeschel JC, Wagner Jr H, Stevens CW, American College of Chest Physicians. Treatment of non small cell lung cancer - Stage IIIA: a CCP evidence-based Clinical Practice guidelines (2nd edition). Chest 2007;132(Suppl. 3):243S-5S.
55. Pauls S, Schmidt SA, Juchems MS, et al. Diffusion-weighted MR imaging in comparison to integrated [(18)F]-FDG PET/CT for N-staging in patients with lung cancer. Eur J Radiol 2010. October 5 [Epub ahead of print].
56. Turkmen C, Sonmezoglu K, Toker A, et al. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high. Clin Nucl Med 2007;32:607-12. (Pubitemid 47220597)
57. Lee BE, Redwine J, Foster C, et al. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3. J Thorac Cardiovasc Surg 2008;135:615-9.
58. Halpern BS, Schiepers C, Weber WA, et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 2005;128:2289-97. (Pubitemid 41507571)
59. Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005;236:1011-9. (Pubitemid 41170866)
60. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s meta-analytic comparison of PET and CT. Radiology 1999;213:530-6. (Pubitemid 29510603)
61. Ventura E, Islam T, Gee MS, Mahmood U, Braschi M, Harisinghani MG. Detection of nodal metastatic disease in patients with non-small cell lung cancer: comparison of positron emission tomography (PET), contrast-enhanced computed tomography (CT), and combined PET-CT. Clin Imaging 2010;34:20-8.
62. Billé A, Pelosi E, Skanjeti A, et al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothoracic Surg 2009;36(3):440-5.
63. Detterbeck FC, DeCamp Jr MM, Kohman LJ, Silvestri GA, American College of Chest Physicians. Lung cancer. Invasive staging: the guidelines. Chest 2003;123:167S-75S.
64. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal negative CT results. Eur J Nucl Med 2000;27:1598-609.
65. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003;123(1 Suppl.):137S-46S. (Pubitemid 36135711)
66. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003;139:879-92.
67. Hoekstra CJ, Stroobants SG, Hoekstra OS, et al. The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer 2003;39:151-7. (Pubitemid 36173615)
68. Jeon TY, Lee KS, Yi CA, et al. Incremental value of PET/CT Over CT for mediastinal nodal staging of non-small cell lung cancer: comparison between patients with and without idiopathic pulmonary fibrosis. AJR Am J Roentgenol 2010;195:370-6.
69. Bruzzi JF, Munden RF. PET/CT imaging of lung cancer. J Thorac Imaging 2006;21:123-36. (Pubitemid 43904260)
70. Eschmann SM, Friedel G, Paulsen F, et al. for staging of advanced non-small cell lung cancer prior to neoadjuvant radiochemotherapy. Eur J Nucl Med Mol Imaging 2002;29:804-8.
71. Seltzer MA, Yap CS, Silverman DH, et al. The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med 2002;43:752-6. (Pubitemid 34663295)
72. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388-93.
73. Jhaveri KS, Wong F, Ghai S, Haider MA. Comparison of CT histogram analysis and chemical shift MRI in the characterization of indeterminate adrenal nodules. Am J Roentgenol 2006;187:1303-8. (Pubitemid 44630836)
74. Savci G, Yazici Z, Sahin N, Akgoz S, Tuncel E. Value of chemical shift subtraction MRI in characterization of adrenal masses. Am J Roentgenol 2006;186:130-5. (Pubitemid 46100373)
75. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 2001;42:1795-9. (Pubitemid 34016347)
76. Gupta NC, Graeber GM, Tamim WJ, Rogers JS, Irisari L, Bishop HA. Clinical utility of PET-FDG imaging in differentiation of benign from malignant adrenal masses in lung cancer. Clin Lung Cancer 2001;3:59-64. (Pubitemid 32904317)
77. Kumar R, Xiu Y, Yu JQ, et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 2004;45:2058-62. (Pubitemid 47611636)
78. Liu T, Xu JY, Xu W, Bai YR, Yan WL, Yang HL. Fluorine-18 deoxyglucose Positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: which one is the best? A Meta-analysis. Clin Oncol (R Coll Radiol) 2010. November 18 [Epub ahead of print].
79. Cheran SK, Herndon JE, Patz EF. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004;44:317-25. (Pubitemid 38609440)
80. Min JW, Um SW, Yim JJ, et al. The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer. J Korean Med Sci 2009;24:275-80.
81. Lohith TG, Kudo T, Demura Y, et al. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer. J Nucl Med 2009;50:1948-53.
82. Metz S, Ganter C, Lorenzen S, et al. Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism. J Nucl Med 2010;51:1691-8.
83. Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;59:78-86. (Pubitemid 38501510)
84. Mac Manus MP, Hicks RJ. Impact of PET on radiation therapy planning in lung cancer. Radiol Clin North Am 2007;45:627-38. (Pubitemid 47238387)
85. Ashamalla H, Rafla S, Parikh K, et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 2005;63:1016-23. (Pubitemid 41505278)
86. Baum RP, Hellwig D, Mezzetti M. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. Q J Nucl Med Mol Imaging 2004;48:119-42. (Pubitemid 39248300)
87. Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004;5:531-40. (Pubitemid 39194041)
88. Mah K, Caldwell C, Ung YC, et al. The impact of (18)FDGPET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002;52:339-50. (Pubitemid 34172999)
89. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42(Suppl. 5):1S-93S. (Pubitemid 32423895)
90. van Der Wel A, Nijsten S, Hochstenbag M, et al. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small cell lung cancer: a modeling study. Int J Radiat Oncol Biol Phys 2005;61:649-55. (Pubitemid 40247958)
91. De Ruysscher D, Wanders S, van Haren E, et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 2005;62:988-94. (Pubitemid 40884408)
92. Fox JL, Rengan R, O'Meara W, et al. Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer? Int J Radiat Oncol Biol Phys 2005;62:70-5. (Pubitemid 40591925)
93. Campione A, Ligabue T, Luzzi L, et al. Late outcome and perioperative complications for surgery of locally recurrent bronchogenic carcinoma. J Cardiovasc Surg 2005;46:515-8. (Pubitemid 41819429)
94. Keidar Z, Haim N, Guralnik L, et al. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 2004;45:1640-6. (Pubitemid 47618469)
95. Hicks RJ, Mac Manus MP, Matthews JP, et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 2004;60:412-8. (Pubitemid 39233459)
96. Hellwig D, Groschel A, Graeter TP, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated nonsmall cell lung cancer. Eur J Nucl Med Mol Imaging 2006;33:13-21. (Pubitemid 41785304)
97. Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to CT scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003;21:1285-92. (Pubitemid 46606405)
98. Mac Manus MP, Hicks RJ, Matthews JP, Wirth A, Rischin D, Ball DL. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for nonsmall cell lung cancer correlates with patterns of failure. Lung Cancer 2005;49:95-108. (Pubitemid 40798098)
99. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
100. Navada S, Lai P, Schwartz AG, Kalemkerian GP. Temporal trends in small cell lung cancer: analysis of the national Surveillance Epidemiology and End-Results (SEER) database [abstract 7082]. J Clin Oncol 2006;24(18S (Suppl.)):384S.
101. Cheng S, Evans WK, Stys-Norman D, Shepherd FA, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2007;2:348-54. (Pubitemid 47181720)
102. Rodriguez E, Lilenbaum RC. Small cell lung cancer: past, present and future. Curr Oncol Rep 2010;12:327-34.
103. Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo A, Genestreti G. Small cell lung cancer. Ann Oncol 2006;17(Suppl. 2):ii5-10.
104. Paesmans M, Sculier JP, Lecomte J, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000;89:523-33. (Pubitemid 30640099)
105. SculierJP, Chansky K, Crowley JJ, VanMeerbeeck J, Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classi- fication of malignant tumours and the proposals for the 7th Edition. J Thorac Oncol 2008;3:457-66. (Pubitemid 351630271)
106. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-60. (Pubitemid 34791094)
107. Simon M, Argiris A, Murren JR. Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol 2004;49:119-33. (Pubitemid 38175439)
108. Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007;2:1067-77. (Pubitemid 350307898)
109. Samson DJ, Seidenfeld J, Simon GR, et al., American College of Chest Physicians. Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(September (3 Suppl.)):314S-23S.
110. Simon GR, Turrisi A, American College of Chest Physicians. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl.):324S-39S. (Pubitemid 47505212)
111. Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007;18:338-45. (Pubitemid 46323103)
112. Brink I, Schumacher T, Mix M, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:1614-20. (Pubitemid 40104607)
113. Azad A, Chionh F, Scott AM, et al. High impact of 18F-FDG PET on mamagement and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol 2010;12:433-51.
114. Kut V, Spies W, Spies S, Gooding W, Argiris A. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucosepositron emission tomography (FDG-PET). Am J Clin Oncol 2007;30:45-50. (Pubitemid 46213824)
115. Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of noncentral nervous system malignancy. Radiology 2003;226:181-7. (Pubitemid 36163927)
116. Yamamoto Y, Kameyama R, Murota M, Bandoh S, Ishii T, Nishiyama Y. Early assessment of therapeutic response using FDG PET in small cell lung cancer. Mol Imaging Biol 2009;11:467-72.
117. Lee YJ, Cho A, Cho BC, et al. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res 2009;15:2426-32.
118. Read WL, Page NC, Tierney RM, Piccirillo JF, Govindan R. The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. Lung Cancer 2004;45:137-42. (Pubitemid 38891474)
119. Travis WD, Muller-Hermelink H-K, Harris CC, Brambilla E. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon, France: IARC Press/World Health Organization Classification of Tumours; 2004. p. 145-95.
120. Gaeta M, Blandino A, Pergolizzi S, et al. Patterns of recurrence of bronchioloalveolar cell carcinoma after surgical resection: a radiological, histological, and immunohistochemical study. Lung Cancer 2003;42:319-26. (Pubitemid 37468545)
121. Raz DJ, He B, Rosell R, Jablons DM. Current concepts in bronchioloalveolar carcinoma biology. Clin Cancer Res 2006;12:3698-704. (Pubitemid 44000249)
122. Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002;74:1640-6.
123. Goudarzi B, Jacene HA, Wahl RL. Diagnosis and differentiation of bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar components with metabolic and anatomic characteristics using PET/CT. J Nucl Med 2008;49:1585-92.
124. Kushihashi T, Munechika H, Ri K, et al. Bronchioloalveolar adenoma of the lung: CT-pathologic correlation. Radiology 1994;193:789-93. (Pubitemid 24366955)
125. Lee KS, Kim Y, Han J, Ko EJ, Park CK, Primack SL. Bronchioloalveolar carcinoma: clinical, histopathologic, and radiologic findings. Radiographics 1997;17:1345-57. (Pubitemid 127466059)
126. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol 2000;174:1005-8. (Pubitemid 30179992)
127. Yap SC, Schiepers C. FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma. Eur J Nucl Med 2002;29:1166-73. (Pubitemid 34985361)
128. Duhaylongsod FG, Lowe VJ, Patz Jr EF, Vaughn AL, Coleman RE, Wolfe WG. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995;60:1348-52.
129. Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998;39:1016-20. (Pubitemid 28270118)
130. Liu S, Cheng H, Yao S, et al. The clinical application value of PET/CT in adenocarcinoma with bronchioloalveolar carcinoma features. Ann Nucl Med 2010;24:541-7.
131. Tan BB, Flaherty KR, Kazerooni EA, Iannettoni MD. The solitary pulmonary nodule. Chest 2003;123(1 Suppl):89S-96S. (Pubitemid 36135706)
132. Leef 3rd JL, Klein IS. The solitary pulmonary nodule. Radiol Clin North Am 2002;40:123-43.
133. Hartman TE. Radiologic evaluation of the solitary pulmonary nodule. Radiol Clin North Am 2005;43:459-65. (Pubitemid 40545045)
134. Gambhir SS, Shepherd JE, Shah BD, et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998;16:2113-25. (Pubitemid 28265048)
135. Jiménez MF, Spanish Video-assisted Thoracic Surgery Study Group. Prospective study on video-assisted thoracoscopic surgery in the resection of pulmonary nodules: 209 cases from the Spanish Video-assisted Thoracic Surgery Study Group. Eur J Cardiothorac Surg 2001;19:562-5. (Pubitemid 32427656)
136. Shure D, Fedullo PF. Transbronchial needle aspiration of peripheral masses. Am Rev Respir Dis 1983;728:1090-2.
137. Siegelman SS, Khouri N, Leo FP, Fishman EK, Braverman RM, Zerhouni EA. Solitary pulmonary nodules: CT assessment. Radiology 1986;160:307-12. (Pubitemid 16070631)
138. Lee JKT, Sagel SS, Stanley RJ, Heiken JP. Computed body tomography with MRI correlation. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1998.
139. Gurney JW, Lyddon DM, McKay JA. Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part II. Application. Radiology 1993;186:415-22. (Pubitemid 23033865)
140. Seemann MD, Seemann O, Luboldt W, et al. Differentiation of malignant from benign solitary pulmonary lesions using chest radiography, spiral CT and HRCT. Lung Cancer 2000;29:105-24. (Pubitemid 30645820)
141. Swensen SJ, Jett JR, Hartman TE, et al. Lung cancer screening with CT: Mayo Clinic experience. Radiology 2003;226:756-61. (Pubitemid 36259152)
142. Swensen SJ, Viggiano RW, Midthum DE, et al. Lung nodule enhancement at CT: multicenter study. Radiology 2000;214:73-80. (Pubitemid 30019872)
143. Erasmus JJ, McAdams HP, Connolly JE. Solitary pulmonary nodules: Part II. Evaluation of the indeterminate nodule. Radiographics 2000;20:59-66.
144. Kim SK, Allen-Auerbach M, Goldin J, et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med 2007;48:214-20. (Pubitemid 47555346)
145. Martins Rde C, Almeida SA, Siciliano AA, et al. Value of 18F-FDG PET/CT as a predictor of cancer in solitary pulmonary nodule. J Bras Pneumol 2008;34:473-80.
146. Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002;43:871-5. (Pubitemid 34747808)
147. Herder GJ, Golding RP, Hoekstra OS, et al. The performance of (18)F- fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 2004;31:1231-6. (Pubitemid 39222486)
148. Gould MK, Maclean CC, Kuschner WG. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914-24. (Pubitemid 32171553)
149. Fletcher JW, Kymes SM, Gould M, et al., Cooperative Studies Group. A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med 2008;49:179-85. (Pubitemid 351225654)
150. Schrevens L, Lorent N, Dooms C, Vansteenkiste J. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist 2004;9:33-643.
151. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med 2009;50(Suppl. 1):11S-20S.
152. Nahmias C, Wahl LM. Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors. J Nucl Med 2008;49:1804-8.
153. Grgic A, Yüksel Y, Gröschel A, et al. Risk stratification of solitary pulmonary nodules by means of PET using 18F-fluorodeoxyglucose and SUV quantification. Eur J Nucl Med Mol Imaging 2010;37:1087-94.
154. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005;128:1717-51. (Pubitemid 40692562)
155. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004;80(Suppl. 1):3-7. (Pubitemid 39382359)
156. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995;36:1825-35.
157. Jiang SX, Kameya T, Shoji M, Dobashi Y, Shinada J, Yoshimura H. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases. Am J Surg Pathol 1998;22:526-37. (Pubitemid 28213738)
158. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934-44. (Pubitemid 28364493)
159. Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 2001;119:1647-51. (Pubitemid 32744917)
160. Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut(neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449(October (4)):395-401.
161. Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757-62. (Pubitemid 47497934)
162. Travis WD, IASLC Staging Committee. Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee. Histopathology 2009;54:3-11.
163. Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:69-85. (Pubitemid 46421900)
164. Ramage JK, Davies AH, Ardill J, et al. UKNETwork for Neuroendocrine Tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54(Suppl. 4):iv1-16.
165. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31. (Pubitemid 23284773)
166. Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value of fluorine-18fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med 1998;25:79-83. (Pubitemid 28107907)
167. Erasmus JJ, McAdams HP, Patz Jr EF, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR 1998;170:1369-73. (Pubitemid 28210961)
168. Chong S, Lee KS, Kim BT, et al. Integrated PET/CT of pulmonary neuroendocrine tumors; diagnostic and prognostic implications. AJR Am J Roentgenol 2007;188:1223-31. (Pubitemid 46668502)
169. Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982-93. (Pubitemid 46919547)
170. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-18. (Pubitemid 47571404)
171. Putzer D, Gabriel M, Henninger B, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50:1214-21.
172. Fanti S, Ambrosini V, Tomassetti P, et al. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomed Pharmacother 2008;62:667-71.
173. Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 2010;37:67-77.
174. Ambrosini V, Nanni C, Zompatori M, et al. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010;37:722-7.
175. Zhernosekov KP, Filosofov DV, Baum RP, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007;48:1741-8. (Pubitemid 47572722)
176. Ambrosini V, Campana D, Bodei L, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010;51:669-73.
177. Campana D, Ambrosini V, Pezzilli R, et al. Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med 2010;51:353-9.
178. Kayani I, Conry BG, Groves AM, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009;50:1927-32.
179. Ambrosini V, Tomassetti P, Castellucci P, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-enteropancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008;35:1431-8.
180. Haug A, Auernhammer CJ, Wängler B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009;36:765-70.